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IGF = insulin-like growth factor; IGFBP = insulin-like growth factor binding protein.
Available online http://breast-cancer-research.com/content/4/1/001
Isoflavones
Isoflavones are polyphenolic compounds naturally present
in foods of plant origin that bear a striking structural simi-
larity to the mammalian estrogens. Soybeans, and prod-
ucts made from soybeans, are by far the richest identified
sources of isoflavones (Table 1), and it has been hypothe-
sized that soy consumption in Asian populations may con-
tribute to the lower incidence of breast cancer and other
hormone-dependent conditions in Eastern versus Western
populations [1]. Isoflavones are capable of binding to
estrogen receptors α and β [2], and they are weak estro-
gens. In common with other weak estrogens, and similar
to selective estrogen receptor modulators such as tamox-
ifen, isoflavones can act as both estrogen agonists and
estrogen antagonists, the latter suggesting potential anti-
proliferative effects of isoflavones on breast tissue. In
Western diets, the lignans, another class of phytoestro-
gens, are quantitatively more important than isoflavones,
but the evidence for lignans possessing estrogenic and/or
anti-estrogenic activities is less well established, and
fewer data are available on their potential beneficial health
effects in humans.
Epidemiology
There are few prospective studies on the effects of
isoflavones on breast cancer risk. In a recent large-scale,
population-based case–control study among Chinese
women, intake of soy foods during adolescence, a period
when breast tissue is particularly sensitive to environmen-
tal stimuli, was associated with a significant reduction in
breast cancer risk in later life [3]. In one of the largest
studies to date, however, neither tofu nor miso consump-
tion had a significant effect on risk of breast cancer among
almost 35,000 women living in Hiroshima and Nagasaki,
Japan [4]. No strong confirmation of an effect of soy on
reducing risk of breast cancer is thus apparent from exist-
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ing studies, but no studies to date have identified an
increased risk of breast cancer associated with elevated
intakes of isoflavones.
Clinical intervention trials
There are many trials in the literature designed to investi-
gate the mechanisms whereby isoflavones may protect
against breast cancer. However, two have raised con-
cerns that isoflavones may exert estrogenic effects on
breast tissue. Petrakis et al. [5] reported an increase in the
presence of epithelial hyperplasia in nipple aspirate fluid
from premenopausal and postmenopausal women follow-
ing a 6-month soy protein intervention, and Hargreaves et
al. [6] reported changes in estrogen-regulated proteins in
nipple aspirate fluid that were indicative of an estrogenic
response among premenopausal women following a 14-
day soy protein intervention. Interestingly, Hargreaves et
al. also reported significantly higher concentrations of
both daidzein and genistein in nipple aspirate fluid than in
paired serum samples, suggesting that isoflavones may
accumulate within the breast ducts [6]. Thus, although
isoflavones are thought to be protective over breast
cancer, it is not clear what effect they may have on breast
tissue, and a bioassay of their effects is needed.
Breast density
The mammographic appearance of the breast differs
between individuals according to the relative proportions
of radiologically dense connective and epithelial tissues,
and of radiologically lucent fat. Increased radiological
density has consistently been associated with an
increased risk of breast cancer since the 1970s. Investiga-
tors have used both qualitative (e.g. Wolfe’s classification
system) and quantitative assessments of breast density
(reviewed in [7]). Quantitative assessments, including
computer-assisted techniques, have generally been asso-
ciated with larger gradients in risk of breast cancer than
qualitative assessments [7] and, to date, the majority of
studies have expressed breast density as a percentage of
the breast occupied by dense tissue. The absolute area of
dense tissue is also associated with risk of breast cancer
(see [7] and references cited therein). In a study among
women from a multi-ethnic population, women with small
total breast areas had higher percent densities but lower
absolute densities than women with large total breast
areas [8]. It is not yet clear, however, whether one method
of expressing breast density is preferable over the other.
In a review of case–control studies using quantitative
methods of determining density, odds ratios for women in
the highest versus lowest extents of density (expressed as
percent density) ranged from 2.1 to 6.0 [7]. These odds
ratios are of a greater magnitude than relative risks
incurred from established breast cancer risk factors such
as early age at menarche and late age at menopause [9].
Potentially, therefore, breast density is an intermediate risk
marker for breast cancer. The mechanism underlying
increased breast density is not fully understood, but a
number of factors have been associated with breast
density changes.
Hormones
There is much evidence that breast density is sensitive to
changes in a woman’s hormonal milieu. Breast density
increases when a woman begins hormone replacement
therapy and decreases when she discontinues (see [10]
and references cited therein). Furthermore, fewer women
have dense breasts after the menopause compared with
before the menopause (reviewed in [7]). It has recently
been shown that the anti-estrogen tamoxifen decreases
breast density [11–13]. A hormonal contraceptive
regimen designed to reduce exposure of the breast to
estrogen and progesterone also reduced mammographic
density [14]. The contrasting effects of estrogens and
anti-estrogens on breast density, and the increased risk of
breast cancer associated with dense breasts, suggest
that it may be useful as a biomarker of estrogenic or anti-
estrogenic effects of a treatment on breast tissue. High
circulating levels of insulin-like growth factor (IGF)-I and
low circulating levels of IGF binding protein (IGFBP)-3
Table 1
Isoflavone content of some common foods
µg/kg wet weight (Da + Gen)
Peas, fresh, cooked nd
Asparagus, cooked nd
Carrots, old, cooked nd
Cucumber, with skin 2.9
Potatoes, old, cooked 7.4
Potatoes, new, cooked 37.5
Red kidney beans, cooked 222.7
Chickpeas, dried, cooked 241.4
French beans, cooked 350.3
Beansprouts, mung, raw 5736
Soy cheese 34,000
Soymilk 44,000
Tofu yogurt 151,000
Soy hot dog, tempeh burger 188,000
Tofu 242,000
Soybeans, dried, cooked 469,000
Miso 1,265,000
Data from Liggins et al. [24], and Reinli and Block [25]. Da, Daidzein;
Gen, Genistein; nd, not detected.c
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have also been associated with increased mammographic
density in premenopausal women [15]. Since IGFs
increase cell proliferation and IGFBPs inhibit proliferation,
it has been suggested that increased breast density might
result from stimulation of cell proliferation by IGF-I and/or
impaired inhibition of proliferation resulting from low levels
of IGFBP-3 [15].
Genetic factors
A family history of breast cancer has been positively asso-
ciated with breast density in some, although not all,
studies. In a cohort study of families with a history of
breast cancer, segregation analysis suggested that a
major autosomal gene influences breast density (see [7]
and references cited therein). It has been suggested that
BRCA1 carriers might have increased breast density due
to mammary epithelial hyperplasia brought about by a
defect in the tumor suppressor gene, but to date this has
not been shown [16]. One study has examined polymor-
phisms in low penetrance genes controlling steroid
hormone metabolism in relation to percent breast density
in women selected on the basis of having Wolfe’s P2 or
DY breast patterns. Sample sizes within genotypes were
small, however, and there were no clear associations
between polymorphisms in CYP17 (T → C substitution at
the 5′ promoter), CYP19 (G → T substitution on intron 6)
or estrogen receptor (C → T substitution on intron 1)
genes and percentage breast density [17].
Diet
Data from both observational and intervention studies on
diet and mammographic densities have suggested that
intakes of certain nutrients can influence breast density. A
2-year low-fat, high-carbohydrate intervention resulted in a
significantly greater decrease in absolute area of breast
density than occurred in controls consuming a self-selected
diet, particularly among women who became post-
menopausal during the study [18]. Further analysis of this
subgroup showed that reduction in total or saturated fat
intake or cholesterol intake was significantly associated with
the decrease in dense area, and the most significant dietary
variable associated with the reduction in percentage density
was reduction in cholesterol intake [19]. In a large cohort
study of breast cancer families, however, increased breast
density was associated with decreased intakes of saturated
fat in premenopausal women [20]. Positive associations
between alcohol intakes and breast density have generally
been found, although in the breast cancer family cohort
white wine was positively associated and red wine nega-
tively associated with density [20]. Positive associations
between breast density and total protein and carbohydrate
intakes [21] and with intakes of vitamins B12, C, and E [20]
have also been described. It remains to be determined,
however, by what mechanism the diet influences breast
density, but it has been suggested that effects may occur
via diet-induced alterations in sex hormone levels [18].
Isoflavones and breast density
If breast density is a marker of breast cancer risk, and
isoflavones protect against breast cancer, more lucent
breasts might be expected to occur in Asian women. Two
cross-sectional studies have examined this. In the first,
premenopausal Japanese women had a significantly lower
proportion of dense breast patterns and a higher propor-
tion of lucent breast patterns than did British women. The
authors did not measure diet, but suggested their findings
might be attributable to environmental factors such as
diet, since they were unable to find correlations between
measurements of endocrine function and breast density
[22]. A second cross-sectional study of a multi-ethnic
population living in Hawaii, in which soy intakes and mam-
mographic densities were investigated, was not able to
confirm this suggestion. Chinese and Japanese women
had higher percent densities than Caucasian and Native
Hawaiian women (but had lower absolute densities), and
there was a significant trend towards higher percent
breast density with increasing quartiles of soy-food intake.
This relationship was not apparent using absolute area of
dense tissue [8]. In a randomized, placebo-controlled trial
of an isoflavone supplement (40 mg clover-derived
isoflavones per day for 1 year) in women selected on the
basis of having Wolfe’s P2 or DY breast patterns, a
decrease in density was observed in the intervention and
placebo groups, but the difference between treatments
was not statistically significant (P > 0.05). When divided
into tertiles according to age, women aged 56–65 years in
the isoflavone group experienced a significantly greater
decrease in density than women aged 56–65 years in the
placebo group (P < 0.05). Sample sizes within tertiles of
age were small, however, and a larger study is needed to
confirm these findings [23]. In a subset of women who
had been genotyped for polymorphisms in CYP17 (T → C
substitution at the 5′ promoter), CYP19 (G → T substitu-
tion on intron 6), and estrogen receptor (C → T substitu-
tion on intron 1) genes, there was no effect of genotype
on change in breast density [17].
Conclusions and future work
Despite the rapid increase in the extent of research into
isoflavones in recent years, there remains a lack of data on
which to base recommendations regarding intakes either
for patients with breast cancer or healthy women wishing
to reduce their risk of breast cancer. Mammographic
breast density has the potential to act as a biomarker of
estrogenic or anti-estrogenic effects of isoflavones on
breast tissue. Further studies are needed to determine the
effects of higher doses of isoflavones, effects of long-term
isoflavone consumption, and effects of isoflavones con-
sumed at various stages of life on breast tissue. Placebo-
controlled intervention trials are the optimal method for
determining the effects of a standardized dose of
isoflavones. Such trials are potentially problematic,
however, in terms of ethical issues associated with the
Available online http://breast-cancer-research.com/content/4/1/001necessity to carry out repeat mammography. Observa-
tional prospective or cross-sectional study designs could
provide information on the effects of dietary isoflavones
without the need for additional mammography, and would
enable large populations to be studied in relatively short
periods of time.
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